The Olfactory-Metabolic Axis: How Smell Shapes Obesity and Type 2 Diabetes
Scientists have discovered that our sense of smell is deeply connected to how our bodies manage weight and sugar. Instead of just being a side effect of being overweight, changes in how we smell might actually help cause or control obesity and diabetes. This suggests that the nose is not just a passive receiver of scent. It is an active participant in our metabolic health.
The Question
Does the olfactory system—the sensory pathway responsible for detecting and processing odors—act merely as a victim of metabolic disease, or does it function as a driver of it? Specifically, the authors of this review seek to determine the mechanistic links between olfactory dysfunction and the progression of obesity and type 2 diabetes. The central tension lies in whether the neurological and structural changes observed in the nose and brain are simply the biological fallout of high blood sugar and excess adipose tissue (fat storage). Alternatively, the olfactory system itself might provide a feedback loop. Such a loop could actively modulate energy balance and glucose homeostasis (the stability of blood sugar levels).
Why The Old Answer Was Incomplete
For much of modern medical history, the olfactory system was treated as a negligible component of human physiology. This was especially true when compared to the massive sensory investments of other mammals [Figure 1a]. In humans, the olfactory bulb—the brain structure that acts as the first relay station for scent information—is proportionally much smaller than in rodents. Because of this, researchers often viewed changes in smell as secondary symptoms. They saw them as "epiphenomena"—side effects that occur alongside a disease but do not influence its course.
The prevailing view held that if an individual with obesity experienced hyposmia (a reduced ability to smell), it was simply a symptom. Researchers thought systemic inflammation or high glucose levels had damaged the delicate sensory neurons. However, this perspective ignored a growing body of evidence suggesting a bidirectional relationship. It failed to account for how sensory cues, such as the smell of food, might preemptively trigger metabolic shifts like insulin release. It also ignored how genetic variations in odor receptors might predispose certain individuals to overeating.
What They Did
To untangle this complexity, the authors synthesized a vast array of evidence. They spanned human clinical observations and preclinical rodent models. They moved beyond simple correlations by examining the entire "olfactory-metabolic axis." This means they traced the flow of information from the periphery to the deep brain.
The investigation focused on three primary anatomical levels: 1. The Main Olfactory Epithelium (MOE): This is the tissue in the nasal cavity where olfactory sensory neurons (OSNs) reside. The authors examined how high-fat diets (HFD) affect the structural integrity of these neurons. They looked specifically at the length of their cilia (tiny, hair-like projections that detect odor molecules) and the rate of cell death, or apoptosis. 2. The Olfactory Bulb (OB): This is the site where sensory neurons project to form glomeruli (spherical clusters of nerve endings). The researchers analyzed how metabolic hormones like insulin, leptin, and ghrelin modulate the electrical excitability of the mitral cells. These are the neurons that transmit refined scent signals to the cortex. 3. Downstream Neural Circuits: This involves the connection between the olfactory system and the hypothalamus. The hypothalamus is the brain's command center for hunger and satiety.
By comparing diverse models—such as diet-induced obesity (DIO) mice, leptin-deficient (ob/ob) mice, and the Goto-Kakizaki rat (a model for type 2 diabetes)—the authors isolated specific drivers. They sought to determine if olfactory deficits were caused by excess fat, insulin resistance, or the specific composition of the diet itself.
What They Found
The review reports that olfactory dysfunction is a hallmark of metabolic disturbance. It is characterized by both structural decay and hormonal dysregulation. At the earliest stage, high-energy diets disrupt the homeostasis of the MOE. This includes shortened cilia length and reduced expression of vital signaling proteins like $G\alpha_{olf}$. There is also an increase in pro-inflammatory responses. This is evidenced by a higher presence of microglia and macrophages (immune cells that respond to tissue damage) .
In the olfactory bulb, the impact is equally profound. The authors note that obesity often leads to a reduction in OB volume. It also leads to a decrease in the number of neurons surrounding the glomeruli. Crucially, they identify a breakdown in hormonal communication: * Insulin and Leptin: These hormones normally help regulate olfactory activity. However, obesity often induces "resistance." In this state, the olfactory system stops responding correctly to these signals. * Ghrelin: In states of hunger, this stomach-derived hormone typically increases olfactory sensitivity to food smells. In obesity, this sensitivity is often impaired. * GLP-1: The authors highlight the role of Glucagon-like peptide-1 (an incretin hormone that stimulates insulin secretion). It plays a vital role in the olfactory bulb. It enhances the excitability of mitral cells to prepare the body for incoming nutrients.
Perhaps most strikingly, the research suggests that the olfactory system can act as a "metabolic gatekeeper." In some rodent models, enhancing olfactory function actually protected mice from becoming obese. For example, blocking certain potassium channels like Kv1.3 produced "super-smeller" mice that were resistant to diet-induced obesity.
What This Changes
The shift from a unidirectional to a bidirectional model changes how we might approach metabolic medicine. If the olfactory system is an active regulator of energy balance, it is no longer just a casualty. It is a lever to be pulled.
The implications are three-fold: 1. Diagnostic Potential: Olfactory performance could serve as a non-invasive biomarker. It might provide an early warning sign of metabolic shifts. This could happen before clinical obesity or diabetes becomes manifest. 2. Novel Drug Delivery: The "nose-to-brain" pathway offers a way to bypass the blood-brain barrier. The authors suggest that intranasal delivery of insulin or GLP-1 analogues could directly target olfactory-metabolic circuits. This could improve glucose regulation .
- Behavioral Intervention: Understanding how scent triggers "cephalic phase" responses is vital. These are the body's anticipatory preparations for food. Therapies could use odor to promote satiety and reduce food cravings.
While these findings are robust in preclinical models, the authors caution that much of the human evidence remains correlational. The immediate next step for the field is to conduct longitudinal human studies. These studies must definitively prove whether restoring a sense of smell can directly drive weight loss and improved glycemic control.